{"filing":{"accession_number":"0001193125-26-286747","cik":"0001750149","ticker":"IKT","company_name":"Inhibikase Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-29","report_date":null,"primary_document":"d68912d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526286747/d68912d8k.htm"},"events":[{"id":14396,"run_id":12816,"accession_number":"0001193125-26-286747","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Stockholders approved six proposals at the Annual Meeting held on June 26, 2026, including election of two Class III directors (Arvind Kush and Dennis Berman), ratification of CohnReznick LLP as auditor, amendments to the Certificate of Incorporation and 2020 Equity Incentive Plan, and advisory votes on executive compensation and voting frequency.","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-06-29","form":"8-K","submitted_at":null,"items":[{"id":11805,"accession_number":"0001193125-26-286747","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2020 Equity Incentive Plan increasing authorized shares by 3,000,000 shares. This is a compensatory arrangement affecting equity grants available to officers and directors. While Item 5.07 also covers the shareholder vote, the substance of Item 5.02 here is the equity plan amendment itself, which is a classic exec_compensation event under the taxonomy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:07:05.579011+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11806,"accession_number":"0001193125-26-286747","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This disclosure describes an amendment to the Certificate of Incorporation to limit officer liability under Delaware law, approved by stockholders at the Annual Meeting and filed with Delaware on June 26, 2026. This is a routine governance matter—a bylaw/charter amendment—that does not fit specific governance categories (not an auditor change, executive appointment/departure, compensation arrangement, or shareholder vote result per se, though the vote occurred). It is administrative in nature and would not materially affect a reasonable investor's assessment of the company's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:07:05.579011+00:00","company_name":"","ticker":null,"filing_date":""},{"id":11807,"accession_number":"0001193125-26-286747","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of an Annual Meeting of stockholders held on June 26, 2026, with detailed voting tallies for six proposals including election of two Class III directors (Arvind Kush and Dennis Berman), ratification of auditor CohnReznick LLP, amendments to the certificate of incorporation and equity incentive plan, and advisory votes on executive compensation and voting frequency. The disclosure is a straightforward shareholder vote results filing with specific vote counts for each proposal.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:07:05.579011+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11805,"accession_number":"0001193125-26-286747","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on stockholder approval of an amendment to the 2020 Equity Incentive Plan increasing authorized shares by 3,000,000 shares. This is a compensatory arrangement affecting equity grants available to officers and directors. While Item 5.07 also covers the shareholder vote, the substance of Item 5.02 here is the equity plan amendment itself, which is a classic exec_compensation event under the taxonomy.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:07:05.579011+00:00","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-06-29"},{"id":11806,"accession_number":"0001193125-26-286747","item_number":"5.03","item_title":null,"event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.92,"reasoning":"This disclosure describes an amendment to the Certificate of Incorporation to limit officer liability under Delaware law, approved by stockholders at the Annual Meeting and filed with Delaware on June 26, 2026. This is a routine governance matter—a bylaw/charter amendment—that does not fit specific governance categories (not an auditor change, executive appointment/departure, compensation arrangement, or shareholder vote result per se, though the vote occurred). It is administrative in nature and would not materially affect a reasonable investor's assessment of the company's financial condition or operations.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:07:05.579011+00:00","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-06-29"},{"id":11807,"accession_number":"0001193125-26-286747","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the results of an Annual Meeting of stockholders held on June 26, 2026, with detailed voting tallies for six proposals including election of two Class III directors (Arvind Kush and Dennis Berman), ratification of auditor CohnReznick LLP, amendments to the certificate of incorporation and equity incentive plan, and advisory votes on executive compensation and voting frequency. The disclosure is a straightforward shareholder vote results filing with specific vote counts for each proposal.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-29T10:07:05.579011+00:00","company_name":"Inhibikase Therapeutics, Inc.","ticker":"IKT","filing_date":"2026-06-29"}]}